Stock Analysis

Apyx Medical Full Year 2022 Earnings: EPS Misses Expectations

Source: Shutterstock

Apyx Medical (NASDAQ:APYX) Full Year 2022 Results

Key Financial Results

  • Revenue: US$44.5m (down 8.3% from FY 2021).
  • Net loss: US$23.2m (loss widened by 53% from FY 2021).
  • US$0.67 loss per share (further deteriorated from US$0.44 loss in FY 2021).
NasdaqGS:APYX Earnings and Revenue Growth March 18th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Apyx Medical EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 4.3%.

Looking ahead, revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

You still need to take note of risks, for example - Apyx Medical has 3 warning signs (and 1 which is potentially serious) we think you should know about.

What are the risks and opportunities for Apyx Medical?

Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide.

View Full Analysis


  • Revenue is forecast to grow 20.87% per year


  • Has less than 1 year of cash runway

  • Does not have a meaningful market cap ($96M)

  • Volatile share price over the past 3 months

  • Currently unprofitable and not forecast to become profitable over the next 3 years

View all Risks and Rewards

Share Price

Market Cap

1Y Return

View Company Report